Navigation Links
Clinical Update - Debio 025 in Hepatitis C
Date:4/28/2008

l Besseghir, CEO of Debiopharm S.A. "This unique mechanism of action is the first alternative treatment to classic HCV therapies."

Debio 025

Debio 025 is a synthetic first-in-class Cyp inhibitor, being tested in humans as a potential anti-HCV drug. Debio 025 binds strongly to Cyp, host cell proteins thought to confer a replication advantage to HCV. Its potent inhibitory activity on the HCV replication was shown in preclinical studies.

Previous results of a phase Ib study demonstrate that Debio 025 monotherapy for 15 days induced a strong anti-HCV effect (3.6 log10 reduction) in HIV-1/HCV co-infected patients. (Hepatology, Vol. 47, No 3, 2008, Flisiak et al. "The Cyclophilin Inhibitor Debio-025 Shows Potent Anti-Hepatitis C Effect in Patients Coinfected with Hepatitis C and Human Immunodeficiency Virus)."

About HCV

HCV is the most prevalent liver disease in the world and is considered by the World Health Organization as an epidemic. Because HCV can infect a patient for decades before being discovered, it is often called the "silent" epidemic. Studies suggest that over 200 million people worldwide are infected with HCV, an overall incidence of around 3.3% of the world's population. In the US alone, nearly 4 million people are or have been infected with HCV and of these, 2.7 million have an ongoing chronic infection, the majority being between 40 to 60 years old. A fourfold increase in the number of adults diagnosed with chronic HCV infection is projected from 1990 to 2015, since most persons with chronic HCV infection have yet to be diagnosed but are likely to come to medical attention in the next decade.

About Debiopharm Group

Debiopharm Group is a global biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates. Debiopharm develops its products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marke
'/>"/>

SOURCE The Debiopharm Group
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Novagali Pharma Successfully Enrolls First Patient in U.S. Phase I Clinical Study with CORTIJECT(R) for Diabetic Macular Edema
2. ESBATechs Lead Antibody Fragment Enters Clinical Development for Ophthalmic Indications
3. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
4. More Clinical Data Required to Support European Approval of CAP Indication for TYGACIL
5. PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy
6. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
7. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
8. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
9. BrainCells Inc. Initiates Phase 2 Clinical Trial with BCI-540 for Depression with Anxiety
10. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
11. AlphaVax Announces Initial Analysis of Data From CMV Phase 1 Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 2013  PENTAX Medical, a healthcare industry leader ... leader in ultrasound imaging, recently announced renewed collaborative ... further innovation in the development of Endoscopic Ultrasound ... and PENTAX Medical endoscopic portfolio have formed one ... systems. This agreement will continue to grow their ...
(Date:5/17/2013)... -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) ( ... announced today that the United States Food and Drug ... application(IND) for ORMD-0801, its oral insulin capsule. ... to proceed," stated Nadav Kidron , ... milestone for Oramed and we look forward to continuing ...
(Date:5/16/2013)... ZURICH , May 17, 2013 ... and Research (A*STAR) and Switzerland,s Cytos ... been dosed in a Phase 1 clinical trial with their ... virus-like particle (VLP) technology. In this first Phase 1 clinical ... and its potential to protect against H1N1 influenza infection will ...
Breaking Medicine Technology:PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems 2PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems 3Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 2Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 2A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 4A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 5A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 6
... with Two Abstracts Accepted for ... November 2008, BRIDGEWATER, N.J., Sept. 4 ... the treatment of,cardiovascular and metabolic disease, today announced ... Company,s board of directors., Peter Garrambone,s career ...
... Group (NYSE: SCR ), a leading manufacturer ... the patented,anti-cancer biotech product Endu (also known as ... Phase IV clinical study., At the request ... clinical study,to further validate the safety and therapeutic ...
Cached Medicine Technology:Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 3
(Date:5/19/2013)... (PRWEB) May 19, 2013 Passages Malibu, ... treatment center, has announced this week the launch of ... the brands’ social media channels. “We are always ... treatment community and to get feedback regarding sobriety, what’s ... CEO and co-founder of the Passages Addiction Treatment ...
(Date:5/19/2013)... Argentina: Yoga classes ( clases de Yoga ) will ... Sivananda Yoga Vedanta Center. The center is located ... are 90 minutes and are offered all week long. ... environment, allowing visitors to enjoy the benefits of Yoga, ... , The Yoga classes follow the following principles: , ...
(Date:5/19/2013)... Ponte Vedra Beach, Florida (PRWEB) May 19, 2013 ... healthcare value and market access, is pleased to unveil ... online trade show environment that provides a powerful array ... solutions to partners in the US and abroad. , ... technology, and will offer attendees the look and feel ...
(Date:5/19/2013)... The legal team at Pulaski & ... concerted effort to connect women and families coping with ... Yaz, Yasmin & Ocella with the legal representation they ... the notorious birth control drugs as well as news ... Yaz, Yasmin & Ocella were very popular birth control ...
(Date:5/18/2013)... Cambridge House of Maryville , a BMA ... area, is hosting a Memorial Day Weekend Barbecue from 11 ... community, which is located at 6960 State Rte. 162 in ... on Medicaid, who need some help to maintain their independence. ... by homemade ice cream for dessert,” says Tracy Skaer-Henry, Administrator ...
Breaking Medicine News(10 mins):Health News:Passages Malibu Announces its Sobriety, Health, and Wellness Social Media Survey 2Health News:Passages Malibu Announces its Sobriety, Health, and Wellness Social Media Survey 3Health News:Clases de Yoga in Buenos Aires, Argentina (Yoga Classes) Now Offered by Sivananda Yoga Vedanta Center 2Health News:HealthEconomics.Com Announces HE-Xpo, a New Virtual Trade Show Devoted to Healthcare Value and Market Access 2Health News:HealthEconomics.Com Announces HE-Xpo, a New Virtual Trade Show Devoted to Healthcare Value and Market Access 3Health News:Yazsideeffects.com Connects Yaz Side Effects Sufferers With Yaz Side Effects Lawyers 2Health News:Metro East Affordable Assisted Living Community to Host Memorial Day Weekend Barbecue 2
... risk of breast cancer, most young women who were treated ... appropriate mammography screening, according to a study in the January ... chest radiation for a pediatric malignancy face a significantly increased ... of breast cancer begins to increase as early as 8 ...
... alternating cycles of chemotherapy and radiation have similar outcomes ... to data from a randomized controlled trial in the ... the National Cancer Institute. , Previous trials in ... followed by radiation was as effective as total removal ...
... Papillary Thyroid Cancer ,A germ-line mutation in the ... with multi-nodular goiter (MNG) and with progression to papillary thyroid ... have MNG progress to PTC, but a genetic link between ... to be involved in thyroid development and is expressed at ...
... HAMILTON, BERMUDA, Jan. 27 Warner Chilcott Limited (Nasdaq: ... year 2009 results.Total revenues for 2009 are expected to be ... results primarily being driven by LOESTRIN 24 FE, DORYX, and ... is anticipated to be in the range of 79% to ...
... to Protect World,s Supply of Donated Blood ... Continued Expansion into New Global Markets and ... PANTHER Instrument- Companies Also Plan Exploratory Collaboration ... Guidance Including Additional Revenue and Profit from ...
... Holmes (Amex: HH ) today announced the ... General Counsel and Corporate Secretary. He has also ... Rosenblum has over 23 years of corporate legal experience ... contract, consumer and other class actions, as well as ...
Cached Medicine News:Health News:Many women who survived childhood cancer do not undergo recommended breast cancer screening 2Health News:Sequential and alternating chemotherapy and radiation equally effective in larynx cancer therapy 2Health News:Also in the Jan. 27 JNCI 2Health News:Also in the Jan. 27 JNCI 3Health News:Also in the Jan. 27 JNCI 4Health News:Warner Chilcott Announces 2009 Financial Guidance 2Health News:Warner Chilcott Announces 2009 Financial Guidance 3Health News:Warner Chilcott Announces 2009 Financial Guidance 4Health News:Warner Chilcott Announces 2009 Financial Guidance 5Health News:Gen-Probe and Novartis Agree to Extend and Expand Blood Screening Collaboration 2Health News:Gen-Probe and Novartis Agree to Extend and Expand Blood Screening Collaboration 3Health News:Gen-Probe and Novartis Agree to Extend and Expand Blood Screening Collaboration 4Health News:Gen-Probe and Novartis Agree to Extend and Expand Blood Screening Collaboration 5Health News:Hooper Holmes Names Mark Rosenblum Senior Vice President, General Counsel and Corporate Secretary 2Health News:Hooper Holmes Names Mark Rosenblum Senior Vice President, General Counsel and Corporate Secretary 3
... reliable strength for temporary wound support. ... compliant and stretchable support material is ... is not required. Predictable absorption. Polyglactin ... inert, nonantigenic, and nonpyrogenic. ,VICRYL (polyglactin ...
Used for implantation to reinforce soft tissue. Supplied sterile in peel-open packages. Intended for one-time use....
... designed for the repair of abdominal hernias. ... has two distinct sides. One side ... layer of sodium hyaluronate and carboxymethylcellulose (similar ... coated side is bioresorbable, providing a temporary ...
... Human explant studies have confirmed Atriums ... maximum clinical performance in hernia repair. ... thinner and less dense hernia mesh ... rigid repair. Since 1994, when Atrium ...
Medicine Products: